Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2018 · 10-Q
Revenue$1.53M$1.53M−85.3% vs Q1 2017 Net Income-$32.35M-$32.35MN/M vs Q1 2017 EPS Diluted-$0.36-$0.36N/M vs Q1 2017 Operating Income-$32,746,122N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,728,665N/M Margins · derivedOperating margin-2140.8%−1929.4 pt vs Q1 2017
Net margin-2114.9%−1892.4 pt vs Q1 2017
ended Mar 31, 2018 · filed May 9, 2018 · 39 d after period end